miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response

Table 3 Combination of clinical model with miRNA predictive model in MED cohort

MED cohort (validation set)	OR (95% CI)	Wald p value	AUC (%)
(A)
Clinical model
Age (5-unit increase)	1.04 (0.65–1.66)	0.88
Gender (male vs. female)	0.58 (0.10–3.31)	0.54	67
Histology (LUSC/NSCLC NOS vs. LUAD)	3.88 (0.79–19.18)	0.1
miRNA model
16-miRNA risk score	1.20 (1.00–1.44)	0.046	76
14-miRNA risk score	1.37 (1.07–1.75)	0.013	82
4-miRNA risk score	2.00 (1.17–3.42)	0.012	81
(B)
Clinical model
Age (5-unit increase)	1.12 (0.67–1.86)	0.67
Gender (male vs. female)	0.46 (0.07–2.98)	0.42
Histology (LUSC/NSCLC NOS vs. LUAD)	2.71 (0.51–14.48)	0.24	77
miRNA model
16-miRNA risk score	1.19 (0.99–1.45)	0.07
(C)
Clinical model
Age (5-unit increase)	1.13 (0.67–1.93)	0.88
Gender (male vs. female)	0.40 (0.06–2.78)	0.54
Histology (LUSC/NSCLC NOS vs. LUAD)	2.40 (0.42–13.79)	0.1	82
miRNA model
14-miRNA risk score	1.37 (1.06–1.77)	0.018
(D)
Clinical model
Age (5-unit increase)	1.14 (0.67–1.94)	0.63
Gender (male vs. female)	0.46 (0.07–3.11)	0.42
Histology (LUSC/NSCLC NOS vs. LUAD)	1.95 (0.33–11.38)	0.46	80
miRNA model
4-miRNA risk score	1.98 (1.11–3.54)	0.022

(A) Performance of single predictive models based on clinical information (age, gender or histology) or miRNA expression (16, 14 and 4 miRNAs). (B–D) Combination of clinical models with 16-miRNA risk score (B), 14-miRNA risk score (C) and 4-miRNA risk score (D)
Odds Ratio (OR)
P value calculated by Wald test and AUC of indicated models are reported in the table

ISSN: 1756-8722